A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

Current Opinion in Pharmacology

Volumn 11, Issue 5, 2011, Pages 457-463

  Pasipanodya, Jotam G ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; DNA REPAIR; DOSIMETRY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 80053120338     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.07.001     Document Type: Review

References (36)

1. World Health Organization, Geneva, Switzerland Global Tuberculosis Control: WHO Report 2010 2010
2. D.A. Mitchison How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis Int J Tuberc Lung Dis 2 1998 10 15 (Pubitemid 28108937)
3. A. Jindani, V.R. Aber, E.A. Edwards, and D.A. Mitchison The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am Rev Respir Dis 121 1980 939 949 (Pubitemid 10118376)
4. S. Morris, G.H. Bai, P. Suffys, L. Portillo-Gomez, M. Fairchok, and D. Rouse Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis J Infect Dis 171 1995 954 960
5. Clinical and Laboratory Standards Institute Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard 2003 Clinical and Laboratory Standards Institute Wayne, PA
6. J.J. Wilkins, G. Langdon, H. McIlleron, G.C. Pillai, P.J. Smith, and U.S. Simonsson Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients Eur J Clin Pharmacol 62 2006 727 735 (Pubitemid 44289503)
7. T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 2004 1642 1651 (Pubitemid 39411014)
8. T. Gumbo, A. Louie, M.R. Deziel, and G.L. Drusano Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance Antimicrob Agents Chemother 49 2005 3178 3181 (Pubitemid 41060557)
9. T. Gumbo, A. Louie, W. Liu, P.G. Ambrose, S.M. Bhavnani, D. Brown, and G.L. Drusano Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth J Infect Dis 195 2007 194 201 (Pubitemid 46080051)
10. T. Gumbo, A. Louie, M.R. Deziel, W. Liu, L.M. Parsons, M. Salfinger, and G.L. Drusano Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin Antimicrob Agents Chemother 51 2007 3781 3788 (Pubitemid 350057771)
11. T. Gumbo, C.S. Dona, C. Meek, and R. Leff Pharmacokinetics- pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs Antimicrob Agents Chemother 53 2009 3197 3204
12. J.G. Pasipanodya, and T. Gumbo Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used Antimicrob Agents Chemother 54 2010 2847 2854
13. T. Gumbo, A. Louie, W. Liu, D. Brown, P.G. Ambrose, S.M. Bhavnani, and G.L. Drusano Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations Antimicrob Agents Chemother 51 2007 2329 2336 (Pubitemid 47047307)
14. S. Srivastava, S. Musuka, C. Sherman, C. Meek, R. Leff, and T. Gumbo Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol J Infect Dis 201 2010 1225 1231
15. R. Jayaram, R.K. Shandil, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis Antimicrob Agents Chemother 48 2004 2951 2957 (Pubitemid 38989160)
16. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R.K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob Agents Chemother 47 2003 2118 2124 (Pubitemid 36753560)
17. J. Pasipanodya, and T. Gumbo An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future Antimicrob Agents Chemother 55 2011 24 34
18. S. Goutelle, L. Bourguignon, P.H. Maire, M. Van Guilder, J.E.J. Conte, and R.W. Jelliffe Pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs: a population modeling and Monte Carlo simulation study Antimicrob Agents Chemother 53 2009 2974 2981
19. C.A. Peloquin, G.S. Jaresko, C.L. Yong, A.C. Keung, A.E. Bulpitt, and R.W. Jelliffe Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide Antimicrob Agents Chemother 41 1997 2670 2679 (Pubitemid 27524738)
20. J.J. Wilkins, G. Langdon, H. McIlleron, G. Pillai, P.J. Smith, and U.S. Simonsson Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients Br J Clin Pharmacol 72 2011 51 62
21. J.J. Wilkins, R.M. Savic, M.O. Karlsson, G. Langdon, H. McIlleron, G. Pillai, P.J. Smith, and U.S. Simonsson Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption Antimicrob Agents Chemother 52 2008 2138 2148 (Pubitemid 351758551)
22. M. Kinzig-Schippers, D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sörgel, and U. Fuhr Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49 2005 1733 1738 (Pubitemid 40631582)
23. D. Almeida, E. Nuermberger, S. Tyagi, W.R. Bishai, and J. Grosset In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis Antimicrob Agents Chemother 51 2007 4261 4266 (Pubitemid 350209875)
24. V.T. Dos, J. Blazquez, J. Rauzier, I. Matic, and B. Gicquel Identification of Nudix hydrolase family members with an antimutator role in Mycobacterium tuberculosis and Mycobacterium smegmatis J Bacteriol 188 2006 3159 3161
25. S.I. Durbach, B. Springer, E.E. Machowski, R.J. North, K.G. Papavinasasundaram, M.J. Colston, E.C. Bottger, and V. Mizrahi DNA alkylation damage as a sensor of nitrosative stress in Mycobacterium tuberculosis Infect Immun 71 2003 997 1000 (Pubitemid 36150797)
26. F. Taddei, I. Matic, B. Godelle, and M. Radman To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly Trends Microbiol 5 1997 427 428 (Pubitemid 27504945)
27. M.E. Rad, P. Bifani, C. Martin, K. Kremer, S. Samper, J. Rauzier, B. Kreiswirth, J. Blazquez, M. Jouan, S.D. van, and B. Gicquel Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family Emerg Infect Dis 9 2003 838 845 (Pubitemid 36801585)
28. C.B. Ford, P.L. Lin, M.R. Chase, R.R. Shah, O. Iartchouk, J. Galagan, N. Mohaideen, T.R. Ioerger, J.C. Sacchettini, and M. Lipsitch Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection Nat Genet 43 2011 482 486
29. D.A. Mitchison, A. Jindani, G.R. Davies, and F. Sirgel Isoniazid activity is terminated by bacterial persistence J Infect Dis 195 2007 1871 1872 (Pubitemid 46870262)
30. Z. Ahmad, L.G. Klinkenberg, M.L. Pinn, M.M. Fraig, C.A. Peloquin, W.R. Bishai, E.L. Nuermberger, J.H. Grosset, and P.C. Karakousis Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig J Infect Dis 200 2009 1136 1143
31. A. Cattamanchi, R.B. Dantes, J.Z. Metcalfe, L.G. Jarlsberg, J. Grinsdale, L.M. Kawamura, D. Osmond, P.C. Hopewell, and P. Nahid Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis Clin Infect Dis 48 2009 179 185
32. G.E. Louw, R.M. Warren, N.C. Gey van Pittius, R. Leon, A. Jimenez, R.H. Pando, C.R. McEvoy, M. Grobbelaar, M. Murray, P.D. van Helden, and T.C. Victor Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux Am J Respir Crit Care Med 2011
33. D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C.R. Horsburgh, J. Horton, and A. Khan Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 2002 528 534
34. W. Burman, D. Benator, A. Vernon, A. Khan, B. Jones, C. Silva, C. Lahart, S. Weis, B. King, and B. Mangura Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis Am J Respir Crit Care Med 173 2006 350 356 (Pubitemid 43209091)
35. G.L. Drusano, C. Fregeau, W. Liu, D.L. Brown, and A. Louie Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model Antimicrob Agents Chemother 54 2010 4368 4372
36. G.L. Drusano, B. Vanscoy, W. Liu, S. Fikes, D. Brown, and A. Louie Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia Antimicrob Agents Chemother 55 2011 2693 2695